Product nameAnti-TPR antibody [EPR8982]
See all TPR primary antibodies
DescriptionRabbit monoclonal [EPR8982] to TPR
Tested applicationsSuitable for: ICC/IF, WBmore details
Unsuitable for: Flow Cyt,IHC-P or IP
Species reactivityReacts with: Human
Does not react with: Mouse, Rat
Synthetic peptide within Human TPR (Cysteine residue). The exact sequence is proprietary.
Database link: P12270
- HeLa + Camptothecin, HeLa, HeLa + Staurosporine, HeLa, 293T and Jurkat cell lysates, HeLa cells
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab170940 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||1/100 - 1/250.|
|WB||1/1000 - 1/5000. Predicted molecular weight: 267 kDa.|
FunctionComponent of the cytoplasmic fibrils of the nuclear pore complex implicated in nuclear protein import. Its N-terminus is involved in activation of oncogenic kinases. Plays a role in the mitotic spindle checkpoint.
Tissue specificityHighest in testis, lung, thymus, spleen and brain, lower levels in heart, liver and kidney.
Involvement in diseaseDefects in TPR are a cause of thyroid papillary carcinoma (TPC) [MIM:188550]. TPC is a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue. Papillary carcinomas are malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. Note=Chromosomal aberrations involving TPR are found in thyroid papillary carcinomas. Intrachromosomal rearrangement that links the 5'-end of the TPR gene to the protein kinase domain of NTRK1 forms the fusion protein TRK-T1. TRK-T1 is a 55 kDa protein reacting with antibodies against the carboxy terminus of the NTRK1 protein.
Note=Involved in tumorigenic rearrangements with the MET or RAF genes.
modificationsPhosphorylated upon DNA damage, probably by ATM or ATR.
Cellular localizationNucleus > nuclear pore complex. Nucleus membrane. Chromosome > centromere > kinetochore. The assembly of the NPC is a stepwise process in which Trp-containing peripheral structures assemble after other components, including p62. Detected at kinetochores during prometaphase.
- Information by UniProt
- Nucleoprotein TPR antibody
- tpr antibody
- TPR_HUMAN antibody
- translocated promoter region (to activated MET oncogene) antibody
All lanes : Anti-TPR antibody [EPR8982] (ab170940) at 1/1000 dilution
Lane 1 : HeLa + Camptothecin cell lysates
Lanes 2 & 4 : HeLa cell lysates
Lane 3 : HeLa + Staurosporine cell lysates
Lane 5 : 293T cell lysates
Lane 6 : Jurkat cell lysates
Lysates/proteins at 10 µg per lane.
Predicted band size: 267 kDa
Immunofluorescence analysis of HeLa cells labeling TPR with ab170940 at 1/100 dilution.